查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1976308

POC脂質檢測市場：依產品類型、技術、應用、最終用戶和通路分類－2026-2032年全球預測

POC Lipid Testing Market by Product Type, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，即時血脂檢測市場價值將達到 3.5486 億美元，到 2026 年將成長至 3.8186 億美元，到 2032 年將達到 5.6932 億美元，年複合成長率為 6.98%。

主要市場統計數據
基準年 2025 3.5486億美元
預計年份：2026年 3.8186億美元
預測年份 2032 5.6932億美元
複合年成長率 (%) 6.98%

簡要概述技術進步、臨床需求和監管澄清如何重塑照護現場血脂檢測的交付模式。

照護現場血脂檢測已成為現代化心臟代謝預防保健的關鍵要素，能夠實現更快速的風險評估和更有效率的臨床工作流程。檢測化學、儀器小型化和介面設計的進步，共同降低了在傳統中心檢查室之外提供臨床實用血脂譜所需的時間和複雜性。因此，臨床醫生、護理團隊和患者現在可以在就診期間更快地獲得三酸甘油酯和膽固醇水平，從而輔助決策。

快速的技術創新、分散的醫療保健模式以及不斷變化的醫療保健系統獎勵，從根本上改變了照護現場血脂檢測的實施和交付方式。

在技​​術創新和不斷發展的診療路徑的驅動下，照護現場脂質診斷的環境正在經歷變革性變化。新的檢測技術以及日益緊湊的桌上型和攜帶式分析儀正在縮小與中心檢查室平台之間的性能差距，照護現場實現更可靠的床邊脂質檢測。這些技術進步輔以試劑穩定性的提升和工作流程的簡化，減輕了非檢查室人員的工作負擔。

分析考察了近期關稅措施如何重塑了整個照護現場血脂診斷生態系統的供應鏈策略和採購方式。

美國近期實施的關稅措施為照護現場血脂檢測設備及耗材的生產商和供應商帶來了複雜的經營環境。部分進口診斷組件關稅的提高導致依賴全球供應鏈的營業單位成本上升，促使其重新評估籌資策略和總到岸成本。因此，採購部門更重視供應商多元化和合約保障，以維持利潤率並確保產品供應。

基於細分市場的洞察揭示了產品類型、用戶環境、技術、通路和臨床應用如何共同決定採用趨勢。

產品細分研究表明，市場可分為耗材和儀器兩大類。耗材包括品管、試劑盒和試劑等關鍵組件，這些組件決定了檢測性能和批間一致性。儀器則包括適用於臨床和檢查室環境的桌上型分析儀，以及針對速度和便攜性進行最佳化的攜帶式分析儀。消費者購買行為的轉變日益凸顯了整體擁有成本和檢驗耗材供應穩定性的重要性，這使得能夠確保試劑長期供應並提供簡單易用的儀器維護流程的製造商獲得了競爭優勢。

區域比較分析：說明不同法規結構、基礎設施成熟度和支付方環境對照護現場血脂檢測部署路徑的影響。

區域趨勢影響照護現場血脂檢測的推廣路徑和營運策略。在美洲，由於相對成熟的醫療保健體系和健全的私人分銷系統，臨床網路優先將快速診斷整合到基層醫療和社區診所中。這種環境促進了桌上型和攜帶式分析儀的普及，從而提高了工作流程效率並增強了病人參與。此外，診斷檢查室的強大基礎也為混合推廣模式提供了契機，這些模式能夠將照護現場平台與中心檢查室標準檢驗。

如何透過檢測創新、綜合服務模式、策略夥伴關係和嚴格的臨床證據產生來建構競爭優勢。

照護現場血脂檢測領域的競爭動態是由產品創新、策略聯盟和臨床檢驗聲明之間錯綜複雜的相互作用所決定的。主要企業正大力投資於檢測方法的開發和易用性工程，以透過準確性、速度和整合能力脫穎而出。隨著企業尋求確保原料供應並降低貿易政策波動帶來的風險，與試劑和組件供應商建立供應鏈合作夥伴關係以及共同開發契約變得越來越普遍。

製造商和醫療保健系統領導者應優先採取策略行動，以增強韌性、加快部署並展現臨床和商業性價值。

產業領導者應優先考慮供應鏈多元化和生產柔軟性，以此來規避貿易政策波動和零件短缺的風險。投資建設區域組裝基地，並為關鍵試劑和設備組件選擇替代供應商，可顯著降低關稅和物流波動帶來的風險。同時，他們也應評估產品設計，以簡化組件的複雜性，並實現高度靈活的生產系統，以及根據需要快速更新法規。

為了支持策略決策，我們採用嚴格的混合調查方法，結合相關人員訪談、監管審查、設備基準測試和專家檢驗。

本分析整合了混合方法研究的洞見，結合了對關鍵產業相關人員的定性訪談以及對監管、臨床和專利文獻的系統性回顧。主要資訊來源包括與臨床實驗室負責人、採購經理、醫療設備工程師和支付方的結構化對話，以檢驗營運挑戰和實施標準。這些觀點與公開的監管文件、臨床試驗註冊資訊和同行評審出版物進行三角驗證，以確保技術和臨床的準確性。

簡明扼要的總結強調了產品、臨床證據和供應鏈策略的必要整合，以實現照護現場血脂檢測的潛力。

照護現場血脂檢測正處於轉折點，其發展動力源於技術進步、醫療模式向分散化轉型以及臨床醫生和患者不斷變化的期望。儀器設計、耗材可靠性和分銷策略的相互作用將決定哪些解決方案能夠有效應用於各種臨床環境。同時，貿易政策和供應鏈現狀的變化​​也要求企業採用更具韌性的商業模式和更務實的生產方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：即時血脂檢測市場：依產品類型分類

  • 消耗品
    • 控制
    • 成套工具
    • 試劑
  • 裝置
    • 桌面分析儀
    • 攜帶式分析設備

第9章：即時血脂檢測市場：依技術分類

  • 層析法
  • 比色法
  • 酵素法
  • 免疫檢測

第10章：即時血脂檢測市場：依應用領域分類

  • 心血管疾病風險評估
  • 糖尿病管理
  • 預防性篩檢

第11章：即時血脂檢測市場：依最終用戶分類

  • 診所
  • 診斷檢查室
  • 家庭測試
  • 醫院

第12章：即時血脂檢測市場：依通路分類

  • 診斷檢查室
  • 電子商務
  • 醫院藥房
  • 零售藥房

第13章：即時血脂檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：即時血脂檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：即時血脂檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國即時血脂檢測市場

第17章：中國即時血脂檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Callegari Srl
  • Chembio Diagnostic Systems, Inc. by BIOSYNEX SA
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical
  • Quidel Corporation
  • SD Biosensor, Inc.
  • Sekisui Medical Co., Ltd.
  • Siemens AG
  • Sienco, Inc.
  • Sinocare Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • VivaChek Biotech（Hangzhou）Co., Ltd.
  • Werfen, SA
Product Code: MRR-DD0700E81D15

The POC Lipid Testing Market was valued at USD 354.86 million in 2025 and is projected to grow to USD 381.86 million in 2026, with a CAGR of 6.98%, reaching USD 569.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 354.86 million
Estimated Year [2026] USD 381.86 million
Forecast Year [2032] USD 569.32 million
CAGR (%) 6.98%

A concise overview of how technological advances, clinical demand, and regulatory clarity are reshaping point-of-care lipid testing delivery models

Point-of-care lipid testing has emerged as a pivotal component in modern preventive cardiometabolic care, enabling more immediate risk assessment and streamlined clinical workflows. Advances in assay chemistry, device miniaturization, and interface design have collectively reduced the time and complexity required to deliver clinically actionable lipid profiles outside traditional central laboratories. As a result, clinicians, care teams, and patients now expect faster access to triglyceride and cholesterol metrics that can inform same-encounter decision-making.

Moreover, the convergence of remote monitoring, telehealth, and decentralized diagnostic strategies is reshaping how lipid testing is deployed in ambulatory settings, community clinics, and increasingly within the home. Regulatory authorities have clarified pathways for point-of-care devices while payers and health systems explore reimbursement and value pathways that reflect the potential for earlier intervention and reduced downstream costs. At the same time, laboratory professionals continue to emphasize the need for rigorous quality assurance, method comparability, and robust clinical validation to preserve diagnostic confidence.

Taken together, these dynamics create both opportunity and obligation for manufacturers, distributors, and healthcare providers. Industry players must balance speed-to-market with demonstrable accuracy, user-centric design, and integration capabilities that support electronic health record interoperability and clinical decision support. As adoption grows, stakeholders who proactively address operational, regulatory, and clinical alignment will be best positioned to capitalize on the shift toward more immediate lipid assessment.

How rapid innovation, decentralized care models, and evolving health system incentives are fundamentally altering point-of-care lipid testing adoption and delivery

The landscape for point-of-care lipid diagnostics is experiencing transformative shifts driven by technological innovation and evolving care pathways. New assay modalities and increasingly compact benchtop and handheld analyzers have narrowed the performance gap with central laboratory platforms, enabling more reliable lipid panels at the point of care. These technical gains are complemented by improved reagent stability and streamlined workflow designs that lower the operational burden on non-laboratory personnel.

Simultaneously, the rise of home testing and patient-centered care models has prompted device makers to focus on usability, connectivity, and data security. Vendors are investing in digital ecosystems that link test results to mobile apps and telehealth platforms, which supports shared decision-making between patients and clinicians. In parallel, clinical practice guidelines and payer policies are adapting to recognize the role of rapid lipid assessment in chronic disease management and preventive screening, which influences procurement priorities and deployment strategies.

Supply chain resilience has also become a strategic imperative, with manufacturers diversifying sourcing and considering regional production hubs to mitigate disruptions. As adoption broadens, partnership models are shifting away from one-size-fits-all sales toward outcome-oriented collaborations that offer bundled device-and-service solutions. Consequently, the market is moving toward a more integrated, patient-focused diagnostic paradigm where speed, quality, and interoperability determine long-term value.

An analytical review of how recent tariff measures have reshaped supply chain strategies and procurement approaches across the point-of-care lipid diagnostics ecosystem

Recent tariff measures implemented in the United States have created a complex environment for manufacturers and suppliers of point-of-care lipid testing equipment and consumables. Increased duties on certain imported diagnostic components have amplified costs for entities reliant on global supply chains, prompting organizations to re-evaluate sourcing strategies and total landed costs. As a direct result, procurement teams are placing greater emphasis on supplier diversification and contractual protections to preserve margin and maintain product availability.

In response, some vendors are accelerating discussions around nearshoring and local assembly to reduce exposure to cross-border tariff volatility. These shifts are not solely procurement-driven; they also influence product design choices as companies seek to reduce reliance on tariffed components by redesigning kits and instruments for regional manufacturing compatibility. At the same time, distributors and healthcare providers are responding by negotiating longer-term agreements and inventory buffers to smooth operational continuity.

Payment and contracting considerations are also adapting, since higher input costs can impact pricing structures and the relative attractiveness of bundled service offerings. Therefore, commercial teams and health system purchasers are increasing the sophistication of total cost assessments, taking into account logistics, regulatory compliance, and potential duties. Ultimately, tariff-related pressures are accelerating strategic shifts toward supply-chain resilience, regional manufacturing partnerships, and contract designs that hedge against future trade-policy changes.

Segment-specific insights revealing how product types, user settings, technologies, distribution pathways, and clinical applications jointly dictate adoption dynamics

Insight into product segmentation reveals that the market is bifurcated between consumables and instruments, with consumables encompassing essential elements such as controls, kits, and reagents that determine assay performance and lot-to-lot consistency, while instruments include both benchtop analyzers suited for clinic and laboratory environments and handheld analyzers optimized for speed and portability. Shifts in purchasing behavior often prioritize total cost of ownership and the availability of validated consumable supplies, so manufacturers that secure long-term reagent supply and deliver intuitive instrument maintenance protocols gain a competitive edge.

From an end-user perspective, adoption patterns vary across clinics, diagnostic laboratories, home testing settings, and hospitals. Clinical decision workflows in hospital and large outpatient settings tend to demand higher throughput and integration with existing laboratory information systems, whereas clinics and home testing emphasize ease of use, minimal sample handling, and rapid result turnaround to support point-of-care consultations. Diagnostic laboratories continue to act as quality hubs, often validating and benchmarking point-of-care outputs to ensure method concordance and to support clinician confidence.

Technology segmentation further highlights the diversity of approaches to lipid measurement. Chromatographic methods and immunoassays offer high analytical specificity and are frequently used in centralized contexts, while colorimetric and enzymatic methods provide simpler, faster pathways to lipid quantification at the point of care. Each technology presents trade-offs among accuracy, cost, and operational complexity; therefore, product positioning must align with the clinical setting and the skill level of intended users.

Distribution channels also shape accessibility and adoption. Diagnostic laboratories, e-commerce platforms, hospital pharmacies, and retail pharmacies each play distinct roles in getting devices and consumables into clinical and consumer hands. E-commerce accelerates direct-to-consumer access and simplifies repeat consumable purchases, whereas hospital and retail pharmacies enable integration into institutional procurement and patient support programs. Finally, application-driven demand-spanning cardiovascular risk assessment, diabetes management, and preventive screening-frames clinical utility and the types of outcome data purchasers require for reimbursement and guideline adoption. Manufacturers that tailor solutions to these application needs and distribution realities can better align product development and commercialization efforts with end-user expectations.

A regional comparative analysis explaining how differing regulatory frameworks, infrastructure maturity, and payer landscapes influence point-of-care lipid testing trajectories

Regional dynamics shape both the adoption trajectory and operational strategies for point-of-care lipid testing. In the Americas, clinical networks emphasize rapid diagnostics integration into primary care and community clinics, supported by relatively mature reimbursement frameworks and a strong private-sector distribution system. These conditions encourage adoption of both benchtop and handheld analyzers that can demonstrate workflow efficiencies and improved patient engagement. Additionally, a robust base of diagnostic labs provides opportunities for hybrid deployment models where point-of-care platforms are validated against central laboratory reference methods.

Across Europe, the Middle East, and Africa, regulatory and reimbursement environments are heterogeneous, driving a more localized approach to market entry. In parts of Europe, well-established health technology assessment mechanisms prioritize clinical validation and cost-effectiveness evidence, which favors devices that can demonstrate quality and outcome benefits. Meanwhile, in the Middle East and Africa, infrastructure gaps and variability in laboratory capacity create demand for portable, easy-to-use devices and consumables that can operate with limited facilities and supply chain constraints. Manufacturers should therefore align regulatory strategies and support models with local health system needs, leveraging partnerships with regional distributors and clinical networks.

Asia-Pacific presents a mix of high-volume urban centers with advanced diagnostic infrastructure and expansive rural areas where decentralized testing can deliver substantial public health value. A strong manufacturing base in several countries supports both regional production and export opportunities, while rapid digital adoption facilitates remote monitoring and integration with national health initiatives. In this region, payers and providers are increasingly receptive to innovations that reduce clinical bottlenecks and enhance chronic disease management, making Asia-Pacific an important locus for scalable deployment and iterative product refinement.

How competitive advantage is being forged through assay innovation, integrated service models, strategic partnerships, and rigorous clinical evidence generation

Competitive dynamics in the point-of-care lipid testing space are defined by a mix of product innovation, strategic partnerships, and claims to clinical validation. Leading organizations invest heavily in assay development and usability engineering to differentiate through accuracy, speed, and integration capabilities. Supply-chain partnerships and co-development agreements with reagent and component suppliers are increasingly common as firms seek to secure raw materials and mitigate risk from trade-policy shifts.

In addition to technical differentiation, commercialization strategies vary widely. Some firms focus on comprehensive service offerings that bundle devices with consumables, training, and remote quality oversight, while others pursue a more modular approach that emphasizes low-cost consumables and broad distribution through e-commerce and pharmacy channels. Strategic alliances with healthcare networks, telehealth providers, and electronic health record vendors are shaping interoperability and care pathway alignment, which in turn influence purchasing decisions among health systems and clinics.

Regulatory compliance and evidence generation remain central to competitive advantage. Companies that prioritize robust clinical evaluation and establish clear pathways for regulatory clearance and post-market surveillance build trust with clinical stakeholders. Moreover, firms that demonstrate responsiveness to payer expectations-by generating real-world evidence of clinical utility in cardiovascular risk assessment, diabetes management, and preventive screening-can materially strengthen their market positioning. Ultimately, success hinges on marrying credible science with scalable commercial models and resilient supply chains.

Prioritized strategic actions for manufacturers and health system leaders to strengthen resilience, accelerate adoption, and demonstrate clinical and commercial value

Industry leaders should prioritize supply-chain diversification and manufacturing flexibility to hedge against trade-policy disruptions and component shortages. Investing in regional assembly hubs and qualifying alternate suppliers for critical reagents and instrument parts can materially reduce exposure to tariff and logistics volatility. At the same time, organizations should evaluate product designs that simplify component complexity, enabling more adaptable production footprints and faster regulatory updates when needed.

Second, companies must accelerate user-centric design and connectivity features for both benchtop and handheld analyzers to drive adoption in decentralized settings and the home. Streamlined workflows, integrated quality controls, and secure data transfer to electronic health records will differentiate offerings and support clinician acceptance. Complementing these technical improvements with structured training programs and remote technical support will reduce user errors and enhance clinical confidence.

Third, manufacturers should deepen engagement with payers, professional societies, and health systems to generate the clinical evidence required for guideline inclusion and reimbursement. Collaborative pilot programs that measure impact on clinical decision-making and downstream outcomes will strengthen value propositions. Parallel commercial strategies should explore bundled service models that combine device placement, consumable supply, and performance monitoring to simplify procurement and improve adherence.

Finally, pursue partnerships that extend beyond traditional distribution-linking with telehealth platforms, chronic care management vendors, and pharmacy networks-to create integrated care pathways. These alliances can expand reach, support patient retention for longitudinal monitoring, and create differentiated offerings that capture greater downstream value.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, device benchmarking, and expert validation to support strategic decision-making

This analysis synthesizes insights derived from a mixed-methods research approach that combines primary qualitative interviews with key industry stakeholders and systematic review of regulatory, clinical, and patent literature. Primary inputs included structured conversations with clinical laboratory directors, procurement leaders, device engineers, and payers to validate operational pain points and adoption criteria. These perspectives were triangulated with publicly available regulatory filings, clinical trial registries, and peer-reviewed publications to ensure technical and clinical accuracy.

Quantitative elements of the methodology comprised device performance benchmarking and comparative assessments of assay principles, focusing on analytical sensitivity, specificity, and user workflow metrics. Supply-chain and trade-policy analyses were informed by customs and tariff schedules, logistics reports, and manufacturer disclosures to capture cost and availability implications. Throughout the process, findings were reviewed by an external panel of clinical and technical experts to stress-test assumptions and identify blind spots.

Limitations of the research include variability in regional data transparency and differences in clinical practice patterns that can influence adoption scenarios. To mitigate these constraints, the methodology emphasizes qualitative contextualization and cross-validation across multiple independent sources. The result is a pragmatic, evidence-focused assessment intended to support strategic decision-making rather than deterministic market projections.

A concise synthesis highlighting the imperative for integrated product, clinical evidence, and supply-chain strategies to realize point-of-care lipid testing potential

Point-of-care lipid testing stands at an inflection point, propelled by technological improvements, a shift toward decentralized care, and evolving expectations from clinicians and patients. The interplay between instrument design, consumable reliability, and distribution strategies will determine which solutions scale effectively across diverse clinical settings. Concurrently, trade-policy shifts and supply-chain realities necessitate more resilient commercial models and pragmatic manufacturing choices.

For stakeholders across the value chain, the imperative is clear: align product development with real-world clinical workflows, invest in evidence generation that addresses payer and guideline requirements, and construct flexible supply chains that support continuity of care. By doing so, organizations can unlock the clinical and operational benefits of rapid lipid assessment while safeguarding quality and accessibility. Ultimately, the most successful players will be those that integrate robust science, user-centric design, and adaptive commercial strategies to meet the needs of an increasingly decentralized diagnostic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. POC Lipid Testing Market, by Product Type

  • 8.1. Consumables
    • 8.1.1. Controls
    • 8.1.2. Kits
    • 8.1.3. Reagents
  • 8.2. Instruments
    • 8.2.1. Benchtop Analyzers
    • 8.2.2. Handheld Analyzers

9. POC Lipid Testing Market, by Technology

  • 9.1. Chromatographic Methods
  • 9.2. Colorimetric Methods
  • 9.3. Enzymatic Methods
  • 9.4. Immunoassays

10. POC Lipid Testing Market, by Application

  • 10.1. Cvd Risk Assessment
  • 10.2. Diabetes Management
  • 10.3. Preventive Screening

11. POC Lipid Testing Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Labs
  • 11.3. Home Testing
  • 11.4. Hospitals

12. POC Lipid Testing Market, by Distribution Channel

  • 12.1. Diagnostic Laboratories
  • 12.2. E-commerce
  • 12.3. Hospital Pharmacies
  • 12.4. Retail Pharmacies

13. POC Lipid Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. POC Lipid Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. POC Lipid Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States POC Lipid Testing Market

17. China POC Lipid Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. A. Menarini Industrie Farmaceutiche Riunite S.r.l.
  • 18.6. Abaxis, Inc. by Zoetis Inc
  • 18.7. Abbott Laboratories
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. bioMerieux SA
  • 18.10. Callegari Srl
  • 18.11. Chembio Diagnostic Systems, Inc. by BIOSYNEX SA
  • 18.12. Danaher Corporation
  • 18.13. EKF Diagnostics Holdings plc
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. General Life Biotechnology Co., Ltd.
  • 18.16. Helena Laboratories Corporation
  • 18.17. Nova Biomedical
  • 18.18. Quidel Corporation
  • 18.19. SD Biosensor, Inc.
  • 18.20. Sekisui Medical Co., Ltd.
  • 18.21. Siemens AG
  • 18.22. Sienco, Inc.
  • 18.23. Sinocare Inc.
  • 18.24. Thermo Fisher Scientific Inc.
  • 18.25. Trinity Biotech PLC
  • 18.26. VivaChek Biotech (Hangzhou) Co., Ltd.
  • 18.27. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POC LIPID TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POC LIPID TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. G7 POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NATO POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)